As a research platform, mSTUDY collates various funding opportunities which may be applicable to our study design. The following links represent current requests for applications (RFAs), program announcements (PAs), and foundation grants which could be helpful if you are considering submitting an mSTUDY sub-study concept sheet:
Notice of Special Interest (NOSI): Research to Address ‘Ending the HIV Epidemic’ Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV
First Submission Date: February 05, 2023
Background: People who inject drugs continue to be a high-risk population for HIV acquisition. A majority of the recent HIV clusters and outbreaks across the U.S. has been linked to people who inject drugs (PWID) and who experience social inequities and health disparities. The many advances in HIV treatment and prevention approaches have not reached PWID and people who use drugs (PWUD) in general. As a result, people with substance use and substance use disorder (SUD) continue to experience gaps in the HIV care continuum, increased burden of comorbidities, and poor health outcomes. This NOSI is designed to enhance implementation and uptake of evidence-based HIV treatment and prevention strategies to meet the objectives of the EHE initiative as it relates to people with substance use and SUD.
The Ending the HIV Epidemic in the U.S.(EHE) is a bold plan announced in 2019 to end the HIV epidemic in the United States by 2030. Multiple agencies across the U.S. Department of Health and Human Services (HHS) participate in this effort. The EHE initiative closely aligns, and is complementary to, President Joe Biden’s National HIV/AIDS Strategy 2022-2025 (the Strategy). Listed below are the four key pillars of the EHE initiative:
- Diagnose all individuals with HIV as early as possible after infection.
- Treat people with HIV rapidly and effectively to reach sustained viral suppression.
- Prevent new HIV transmissions by using proven interventions, including pre-exposure prophylaxis (PrEP) and syringe services programs (SSPs).
- Respond quickly to potential HIV outbreaks to get needed prevention and treatment services to people who need them.
Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine
First Submission Date: June 05, 2023
Expiration Date: May 08, 2026
Background: Variable responses to ART are due at least in part to human genetic variants that affect drug metabolism, drug disposition, and off-site drug targets. Defining effects of human genetic variants on HIV treatment toxicity, efficacy, and pharmacokinetics has far-reaching implications. Substances of abuse (opioid, stimulants, nicotine, anxiolytics, alcohol, etc.) and its treatments (methadone, buprenorphine, extended naltrexone, etc.) may interact with ART, altering its bioavailability, its safety, and its efficacy. It is known that nevirapine and efavirenz increase methadone clearance. New evidence demonstrates that variabilities in responses to ART depend in part on genetic variants for certain drugs of abuse and its therapies. For instance, a NR1I3 gene variant affected methadone clearance only in those taking efavirenz. Two other genetic variants in the ABCB1 and CYP2B6 genes decreased methadone clearance. More research, though, is necessary to better understand the role of pharmacogenomics in people with HIV (PLWH) with substance use disorders (SUD).
NIDA is interested in receiving research proposals focusing on studying pharmacogenomics in PLWH with SUD as a crucial step in the science of Precision Medicine, in the path of personalized care for HIV and drug abuse..
Topics include but are not limited to:
- Correlation of genomics with ART, drugs of abuse and its treatments with absorption, distribution, metabolism, and elimination (ADME)
- Population differences in genotypic frequencies
- Multiple genetic variants and its consequences
- Clinical phenotypes and its pharmacogenomic correlations
- Genomic-wide association studies (GWAS)
- Medical consequences of pharmacogenomic interactions with SUD-safety and efficacy
- Phenotypic and genomic at-risk populations; twin studies
- Geographical correlations (rural, islands, international); areas of wide (e.g., Africa) vs limited (e.g., Iceland) genetic diversity
- Study design and methodology (e.g., prospective targeted vs observational), cost-effectiveness
Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)
First Submission Date: February 07, 2023
Expiration Date: November 16, 2024
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this FOA.
Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R01 Clinical Trials Not Allowed)
First Submission Date: July 10, 2023
Expiration Date: August 11, 2023
The purpose of this FOA is to encourage research using data science and computational approaches to generate new insights into mechanisms and consequences of the interaction of HIV and addictive drugs. Development and application of novel computational, bioinformatics, statistical, and analytical approaches can help to identify the effects of interaction between the HIV virus and addictive drugs on viral replication, reservoirs, therapy, latency, and disease progression, as well as reveal new aspects of addiction biology.
Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
First Submission Date: July 10, 2023
Expiration Date: August 14, 2025
This Notice of Funding Opportunity (NOFO) supports projects aimed at elucidating neuroimmune and neuronal-glial pathophysiological mechanisms of HAND using ex vivo culturing platforms derived from human iPSCs, in the presence and/or absence of addictive substances. It is expected that the latest state-of-art ex vivo culture technology will be used to create unbiased, reproducible analysis of genetics and epigenetics, neuroglial interactions, and neuroimmune cell activities at the single cell to neural circuit levels. Investigators are encouraged to exploit the most current genomic editing tools such as CRISPR, single cell and omics analysis, and imaging approaches to address outstanding questions of the mechanisms by which HIV and addictive substances act separately and/or synergistically to produce neurodegeneration.